Introduction
Cancer has been the leading cause of death in Korea since 1983 [1] and is the most burdensome disease [2] . More than 200,000 new cancer cases are diagnosed in Korea each year, and cancer is responsible for one in four total deaths [3] . This article reports the most recent nationwide cancer statistics in Korea, including incidence, mortality, survival, prevalence, and their trends.
Data sources
The Ministry of Health and Welfare, Korea, initiated a nationwide hospital-based cancer registry called the Korea Central Cancer Registry (KCCR) in 1980. The registry collected 80-90% of cancer cases annually from more than 180 training hospitals throughout the country. In 1999, the KCCR expanded cancer registration to cover the entire population under the Population-Based Regional Cancer Registry program. Details of the history, objectives, and activities of the KCCR have been documented elsewhere [4] . Incidence data for 1999-2011 were obtained from the Korea National Cancer Incidence Database (KNCI DB). The completeness of incidence data for 2011 was 97.1%, as determined by the Ajiki method [5] .
Cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition [6] and converted according to the International Classification of Diseases, 10th edition (ICD-10) [7] . The survival analysis used 2,197,413 cancer cases first diagnosed between 1993 and 2011 from the KNCI DB, and followed vital status until December 31, 2012.
Mortality data from 1983 to 2011 were obtained from Statistics Korea [1] . Cause of death was coded and classified according to ICD-10 [7] . Population data were also obtained from Statistics Korea using the resident registration population on July 1 of specified years.
Analysis
Crude rates (CRs) and age-specific rates of cancer incidence and mortality were calculated. Age-standardized rates (ASRs) were calculated using Segi's world standard population [8] . Cumulative risks of cancer, which represent the probability of developing cancer during one's lifetime, were also calculated. Changes in the annual ASRs of cancer incidence were examined by calculating the annual percentage change over a time period as (exp(b)-1)×100, where b is the slope of the regression of log ASR for a given calendar year [9] .
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Limited-duration prevalent cases on January 1, 2012. These are patients who were diagnosed between January 1, 1999 and December 31, 2011 and who were alive on January 1, 2012. Multiple primary cancer cases were counted multiple times, b) Includes the gallbladder and other/unspecified parts of the biliary tract. Table 1 . 2011 Cancer incidence, prevalence, and deaths by sex in Korea between January 1, 1999 and December 31, 2011, and still alive on January 1, 2012. We calculated limited-duration prevalences, namely, 1-and 5-year prevalences. For example, the 5-year prevalence was calculated as the number of people alive on January 1, 2012 who had been diagnosed with cancer within the previous 5 years. We applied this counting method using the SEER*Stat software [10] to calculate the number of cases while adjusting for patients lost to followup.
The survival duration for each case was determined as the interval between the date of initial diagnosis and the date of death, date of loss to follow-up, or closing date for followup. Observed survival rates were calculated using the life-table method and relative survival rates with the Ederer II method [11] were based on an algorithm written in SAS by Paul Dickman [12] , with some minor modifications.
Selected Findings

Incidence
The overall number of incident cancer cases, deaths, and prevalent cases by sex and cancer site for 2011 in Korea are shown in Table 1 
Mortality
A total of 71,579 cancer deaths were reported in Korea for 2011, accounting for 27.8% of all deaths (Table 3 ). In 2011, the CRs per 100,000 for all sites combined were 178.9 and 106.7 in males and females, respectively. The ASRs per 100,000 for all sites combined were 137.3 and 59.1 for males and females, respectively. Cancers of the lung, liver, stomach, and colon/rectum were the main leading causes of cancer death, together accounting for approximately 61.7% of all cancer deaths in 2011 (Table 4) .
In males, the five most common sites of cancer death in 2011 were lung (CR, 45.9; ASR, 35.0), liver (CR, 32.8; ASR, 24.3), stomach (CR, 25.2; ASR, 19.3), colon and rectum (CR, 17.3; ASR, 13.4), and pancreas (CR, 9.5; ASR, 7.3). In women, lung cancer (CR, 17.4; ASR, 9.1) was the leading cause of cancer death in 2011, followed by stomach (CR, 13.6; ASR, 7.1), colon and rectum (CR, 13.2; ASR, 6.9), liver (CR, 10.9; ASR, 6.1), and breast (CR, 8.0; ASR, 5.2).
Trends in cancer incidence
The cancer incidence rates from 1999 to 2011 in Korea for all sites combined and for selected sites are shown in Tables  5-7 . The incidence for all sites combined increased by 3.4% per year (1.6% in males, 5.4% in females) from 1999 to 2011. The rapid increase in cancer incidence is also illustrated in Fig. 1 .
The incidence rates for colorectal and thyroid cancers have continued to increase in both sexes, as have those for prostate cancer in males and breast cancer in females (Fig. 2) . CNS, central nervous system. a) Age-adjusted using the world standard population, b) Includes the gallbladder and other/ unspecified parts of the biliary tract. Includes the gallbladder and other/unspecified parts of the biliary tract. Other and ill-defined Includes the gallbladder and other/unspecified parts of the biliary tract. Lip, oral cavity, and pharynx Other and ill-defined Includes the gallbladder and other/unspecified parts of the biliary tract. Other and ill-defined In contrast, the incidences of liver cancer in both sexes, lung cancer in males, and cervical cancer in females have decreased. Notably, thyroid cancer increased by 23.3% per year rapidly in both sexes, and became the most common cancer since 2009. Improvements in the sensitivity of diagnostic techniques for thyroid cancer, such as the advent of ultrasound and fine-needle aspiration, have enabled the detection of small-sized thyroid cancers. Furthermore, screening rates have increased. Therefore, the increased incidence of thyroid cancer might reflect the identification of previously undetected diseases rather than a true increase in the occurrence of thyroid cancer [13] [14] [15] [16] . Furthermore, due to the construction of a 1999-2011 KNCI DB, the completeness of the Korean cancer registry data has improved gradually, and this may have contributed, in part, to the gradual overall increases in cancer incidence, particularly among elderly patients.
Age-specific incidence rates
The most common cancer sites by sex and age group in 2011 are shown in Table 8 . Leukemia and thyroid cancer were the most common cancer in both sexes in patients aged 0-14 and 15-34 years, respectively. For males, stomach cancer was the most common cancer in those aged 35-64, while lung cancer was more frequent among patients aged 65 and over. Thyroid cancer was the most common cancer in females aged 35-64 years, and colorectal cancer was the most common cancer among older females aged 65 and over.
The age-specific incidence rates for selected cancers in males and females in 2011 are shown in Fig. 3 . The graphs show that the incidences of stomach, lung, liver, and colorectal cancers increased gradually with age. Incidences of breast and thyroid cancers in females were highest among patients in their late 40s and early 50s, respectively, and leveled off thereafter. The age-specific pattern of breast cancer is different from those in Western countries [17] .
Trends in cancer mortality
The trends in cancer deaths for all sites combined and for selected sites are shown in Figs. 1 ASRs of mortality due to lung cancer have decreased slightly in both males and females since 2002. The ASRs of mortality due to stomach and uterus cancers also have decreased continuously. Along with significant increases in colorectal, prostate, and female breast cancer incidence rates, mortality rates of these cancers have also continued to increase.
Survival rates
The trends in relative survival for all sites combined among both sexes by year of diagnosis from 1999 to 2011 are shown in Fig. 5 . The relative survival for all sites combined Other and ill-defined increased with year of diagnosis, and also increased when we excluded thyroid cancer cases in our analysis. Table 9 shows the 5-year relative survival rates for four diagnosis periods: 1993-1995, 1996-2000, 2001-2005, and 2007-2011 . Patients who were diagnosed with cancer in the most recent period (2007-2011) had a 5-year relative survival rate of 66.3% for all sites combined in both sexes (57.6% in males and 75.2% in females). When compared with earlier periods, notable improvements in the 5-year relative survival rates were observed for all sites combined. The higher cancer survival rate in females might be partly explained by cancers common in females (e.g., thyroid, breast, and cervix uteri cancers) having relatively good prognoses.
When examined by year of diagnosis and cancer site, the 5-year relative survival rates appeared to be higher for most major cancers in patients diagnosed from 2007 to 2011 compared with those diagnosed from 1993 to 1995, with the exception of pancreatic cancer. The greatest improvements were seen in cancers of the prostate, stomach, leukemia, lip/oral cavity/pharynx, and non-Hodgkin lymphoma. The improving survival rates could be attributable to early detection and improved treatments [18, 19] , but this requires further evaluation. Only pancreatic cancer showed no improvement in 5-year relative survival rate compared with 1993-1995. A lack of progress in early detection and treatment could explain the observed absence of improvement in the survival rate for pancreatic cancer [20] .
Prevalence rates
The cancer prevalence rates by sex and cancer site on Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2011 and who were alive on January 1, 2012. Multiple primary cancer cases were counted multiple times, b)
Age-adjusted using the world standard population, c)
Includes the gallbladder and other/unspecified parts of the biliary tract. 
